我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
, {! ?" @" U+ r+ Author Affiliations
8 b# b' f, Y5 K8 i7 D8 }' r+ c% x
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
+ S) U4 K8 D% Q- N2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 l# D$ P! h* {* o2 U; n& U2 v. t$ Y4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
: N) z7 j$ v% |* }5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 t6 i: K" h4 O/ q7 Y' q6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7Kinki University School of Medicine, Osaka 589-8511, Japan
5 q% a; m2 Q, ?. v# a8Izumi Municipal Hospital, Osaka 594-0071, Japan
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.

- I" ?$ ~+ ]' `: \& w( K3 {9 T

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type

. B1 V  Z: T  V1 }0 DAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

2 S2 v( N- Y7 h% k$ ?Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

6 P2 P' n# ~$ ?! NPublished online on: Thursday, December 1, 2011

Doi: 10.3892/ol.2011.507
$ l- Q( E- Z' N& S  c$ t
Pages: 405-410
, S: B3 Q! p+ J& d$ j3 n
! t) o) h) M6 n5 J" G4 Q7 WAbstract:
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

- N& a% G/ a, {9 k. d

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
0 [2 x! V( X- F3 }/ RF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
+ Author Affiliations
, i, Y! F) X. l6 L6 T1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
/ Q: y& F0 D; v8 s5 x( G$ u2 A7 q2Department of Thoracic Surgery, Kyoto University, Kyoto
  f% }: g1 V/ ?; W5 C3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
6 m) x7 @% ^* }: I- O7 U$ |Revision received November 11, 2010.
8 i7 K2 ^% h6 a7 o9 ~Accepted November 17, 2010.
) N$ S7 u: B2 b6 dAbstract
2 o6 C4 T# |. K- r# y* qBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
5 D$ B! Y3 k9 h! o今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？
) G% X4 v" u( @" i6 C

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
+ b( i5 Y; B# z% y0 ]+ Whttp://clinicaltrials.gov/ct2/show/NCT01523587
% h5 j3 h1 c. u" X
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
) L" o$ y& w. m4 y) chttp://clinicaltrials.gov/ct2/show/NCT01156545

从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

                               
登录/注册后可看大图

' a5 t2 g/ Z5 T2 D1 y从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
, C; s# V7 }- K! K" _" M  x至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
' P2 N* z0 {! u# d不错。